Thalia Therapeutics (LSE:THAT) has signed a Clinical Trial Agreement, a decisive step forward in advancing a treatment for Leukaemia. The Company is developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. An agreement with City of Hope, one of the world's leading cancers research and treatment centres supports completion of Phase 1 […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.